🇺🇸 FDA

Drug profile · INN

penicillamine

LUXZYLA

approved
US status
approved
Patents linked
8
News articles
0

Quick answer

penicillamine (LUXZYLA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN penicillamine
Brand LUXZYLA
Route ORAL
Formulation CAPSULE
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 12331026

    Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12188005

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12156877

    Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12036231

    Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11945822

    Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11897932

    Receptors for ligand-dependent transcriptional regulation

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11801234

    Methods of treating APOL-1 dependent focal segmental glomerulosclerosis

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is penicillamine?

penicillamine (LUXZYLA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for penicillamine?

LUXZYLA is a marketed brand name for penicillamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of penicillamine?

penicillamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.